Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (August 2020)
21 slides from Cynata Therapeutics's investor presentation, Aug 14, 2020
Slide 1: ASX Announcement: Cynata Investor Presentation
ASX ANNOUNCEMENT 14 August 2020 Cynata Investor Presentation For personal use only Melbourne, Australia; 14 August 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has today released a new investor presentation. This will be used
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited August 2020
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Cynata is a clinical stage biotech with a scalable proprietary stem cell platform
Cynata Therapeutics is a clinical stage biotech with a highly scalable, proprietary platform for developing stem cell therapeutics For personal use only Our focus Financial information Share price (5-Aug-20) A$0.63 Utilise our proprietary CymerusTM platform technology to develop commercially scalabl
Slide 5: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Crohn’s Disease Others Osteoarthritis (funded by NHMRC) Fistula Coronary Artery Potential future Disease target areas Phase 3 ready Diabetic wounds Graft vs Host Disease (GvHD) Licensed Cymer
Slide 6: Cynata's MSCs in COVID-19 infection
Cynata’s MSCs in COVID-19 infection For personal use only Increased global interest in the potential of MSCs to treat complications of COVID-19, with early studies demonstrating potential utility1 COVID-19 is a respiratory virus that in some patients causes severe complications, particularly inv
Slide 7: MEND trial | Overview of clinical trial COVID-19 patients
MEND trial | Overview of clinical trial COVID-19 patients For personal use only Target 24 adult patients with COVID-19 admitted to intensive care with compromised lung population function, which can ultimately progress to ARDS Respiratory distress (+ CRS and sepsis) represent significant unmet n
Slide 8: Osteoarthritis | New Phase program
Osteoarthritis | New Phase 3 program Funded by National Health and Medical Research Council For personal use only 30,000,000 ~US$11.6B1 People in the USA affected by osteoarthritis Forecast global market opportunity by 2025 Estimated market size Assess the effect of Cymerus MSCs on clinical outcom
Slide 9: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities For personal use only TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Phase 3 Osteoarthritis (OA)1 ready US$11.6 bn Graft vs. Host Disease (GvHD)2 US$0.3 bn Phase 2 Critical limb ready ischemia (CLI)3 US$1.4 bn Acute respiratory distress syndrome (ARDS
Slide 10: Valuation comparison to other stem cell-therapy product companies
Valuation comparison to other stem cell-therapy product companies For personal use only US$3.01bn3 Significant upside potential for Cynata US$1.25bn1 US$1.00bn2 Market US$0.05bn1 Capitalisation: Company GvHD: Phase 1 complete 7 cancer immunotherapy Clinical stage Parkinson’s disease Multiple targets
Slide 11: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Current conventional MSC manufacturing process is impractical For personal use only Cells donated Conventional process MSCs Cells from Cellular therapies MSC isolation MSC expansion multiple donors administered Substantial variability Limit
Slide 12: Cynata has the only platform able to produce commercial quantities of MSCs from a single source
Cynata has the only platform in the world able to produce commercial quantities of MSCs from a single source Conventional process Cymerus™ Significance for Cynata For personal use only Continuous supply of One donor, one time Lower cost; simplified logistics; highly Donors new donors required (com
Slide 13: Cymerus process addresses key areas the FDA is likely to focus on
Cynata‘s Cymerus process actively addresses some of the key areas that the FDA is likely to focus on For personal use only Potential issues raised Key advantages underpinning CymerusTM: “The issue of reliable prediction Product derived from a single donor provides a highly of biological activity is
Slide 14: World-first allogeneic iPSC-derived cell therapy Phase 1 trial in steroid-resistant acute GvHD
World-first allogeneic iPSC-derived cell therapy Phase 1 clinical trial in steroid-resistant acute GvHD completed, with compelling results For personal use only Key clinical trial results (1⁰ evaluation at Day 100) Two year follow-up All 53% 87% Overall endpoints ≥87% survival 60% achieved Complete
Slide 15: Cynata is executing on a clear scientific and commercial vision
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value Multiple options to create For personal use only shareholder value case study Build value in platform independently Exclusive global licence in GvHD (e.g. continue runnin
Slide 16: Broad, advanced development pipeline with multiple near-term catalysts
Broad, advanced development pipeline with multiple near-term catalysts For personal use only Pre-clinical Phase 1 Phase 2 Phase 3 Upcoming catalysts Phase 2 trial expected to commence end of CY20 GvHD Responsible for all ongoing development Potential A$100m+ milestone and via global license agreemen
Slide 17: Investment Summary
Investment Summary For personal use only Cymerus platform technology enables commercial-scale production of mesenchymal stem cells Scalable, globally applicable Fully patented process overcomes multiple issues with today’s on-market solutions technology Value of platform to a range of diseases
Slide 18: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Slide 19: Appendix
For personal use only Appendix
Slide 20: Globally experienced board and management team
Globally experienced board and management team For personal use only Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr Geoff Brooke Dr Darryl Maher Dr Kilian Kelly Chairman Managing Director / CEO Non-Exec Director Non-Exec Director Non-Exec Director Chief Operating Officer CEO, Obsidian 30
Slide 21: Pre-clinical studies | Existing target areas
Pre-clinical studies | Existing target areas For personal use only Proof of Disease target Pre-clinical Global market Partner concept Key highlights area trials started opportunity* completed Study demonstrated effectiveness of Cymerus MSCs in sheep with ARDS in association US$2.5bn ARDS with th
Cynata Therapeutics — Investor Presentation (August 2020) on 6ix